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Rapamycin is an effective inhibitor of human renal cancer meta- Renal cell cancer (RCC) is the most common cancer
stasis. of the kidney, occurring in over 27,000 individuals in the
Background. Human renal cell cancer (RCC) is common United States alone each year [1]. Although it accountsand is 10 to 100 times more frequent in patients with end-stage
for only 1% to 3% of visceral malignancies, RCC posesrenal disease (ESRD) and candidates for renal transplantation.
a significant health problem because the clinical course isTreatment of metastatic RCC is largely ineffective and is fur-
ther undermined by immunosuppressive therapy in transplant unpredictable and the prognosis is dismal once distance
recipients. A treatment regimen that prevents transplant rejec- metastasis develops [2]. Current treatments of RCC in-
tion while constraining RCC progression would be of high value. clude radical resection of tumor mass and immunother-Methods. We developed a human RCC pulmonary metasta-
apy with cytokines such as interferon  and/or interleu-sis model using human RCC 786-O as the tumor challenge and
kin-2 (IL-2) [3].the severe combined immunodeficient (SCID) beige mouse as
the host. We explored the effect of rapamycin, cyclosporine, or Most types of RCC are derived from proximal renal
rapamycin plus cyclosporine on the development of pulmonary tubular cells, show mutations and/or loss of both copies of
metastases and survival. The effects of the drugs on tumor
the von Hippel-Lindau tumor suppressor gene (VHL gene)cell growth, apoptosis, and expression of vascular endothelial
[4, 5] and are among the highly vascularized tumors ofgrowth factor (VEGF-A) and transforming growth factor 1
(TGF-1) were also investigated. epithelial origin. Factors implicated in such hypervascular-
Results. Rapamycin reduced, whereas cyclosporine increased, ity include angiogenic factors such as vascular endothelial
the number of pulmonary metastases. Rapamycin was effective growth factor (VEGF-A), transforming growth factor-1
in cyclosporine-treated mice, and rapamycin or rapamycin plus
(TGF-1), platelet-derived growth factor (PDGF), andcyclosporine prolonged survival. Rapamycin growth arrested
transforming growth factor- (TGF-) [6–8]. In particu-RCC 786-O at the G1 phase and reduced VEGF-A expression.
Immunostaining of lung tissues for von Willebrand factor was lar, the expression of VEGF-A is found to be high and
minimal and circulating levels of VEGF-A and TGF-1 were appears directly related to functional mutations and/or
lower in the rapamycin-treated mice compared to untreated loss of VHL gene [5, 8, 9]. Indeed, reintroduction ofor cyclosporine-treated mice.
wild-type VHL gene has been shown to down-regulateConclusion. Our findings support the idea that rapamycin
expression of VEGF-A at the level of mRNA [10]. Itmay be of value for patients with RCC and that its antitumor
efficacy is realized by cell cycle arrest and targeted reduction has also been demonstrated that introduction of the wild-
of VEGF-A and TGF-1. A regimen of rapamycin and cyclo- type VHL gene in to human RCC 788-O reduces TGF-1
sporine, demonstrated to be effective in reducing acute rejec- overexpression [6].tion of renal allografts, may prevent RCC progression as wel,
Rapamycin is a macrolide isolated from Streptomycesand has the potential to prevent mortality due to RCC in
patients with ESRD who have received renal allografts. hygroscopius. It binds to a highly conserved cellular pro-
tein FKBP12 and the rapamycin/FKBP12 complex tar-
gets and inactivates mTOR, considered as a master switch
for cell cycle progression. Rapamycin was approved by
United States Federal Food and Drug Administration1See Editorial by Sukhatme and Strom, p. 1160.
for use in organ transplantation in conjunction with
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despite being a potent immunosuppressant, has been use of 7700 Sequence Detector (Applied Biosystems,
Foster City, CA, USA). We designed and validated oli-shown to inhibit the growth a variety of tumor cell lines.
In studies carried out in our laboratory, we found that gonucleotide primers and fluorogenic probes for the
measurement of mRNAs by real-time quantitative PCRrapamycin prevented the growth and metastatic progres-
sion of murine renal cancer [11]. In the current investiga- assay (Table 1). We used 18S ribosomal RNA (rRNA)
amplicon to develop the standard curve. 18S rRNA wastion, we explored the antitumor efficacy of rapamycin
with the use of a well-characterized human RCC 786-O measured in each sample and used as the internal control
to normalize RNA yield.as the tumor inoculum in T-cell, B-cell and NK-cell defi-
cient severe combined immunodeficient (SCID) beige
Enzyme-linked immunosorbent assaymice. Our selection of RCC as the tumor candidate to
examine rapamycin’s effectiveness was dictated in part RCC were incubated in the absence or presence of
rapamycin, CsA, rapamycin and CsA, and cell free cul-by the observation that the incidence of RCC in the end-
stage renal disease (ESRD) population is 10 to 100 times ture supernatants were collected and stored at –20C
until measurement of cytokine levels by enzyme-linkedhigher than that in general population [12–14] and should
rapamycin prove to be effective, a novel therapy to re- immmosorbent assay (ELISA). Cell count was performed
as well at the time of supernatant collection and cytokineduce high mortality rate in renal allograft recipients who
develop RCC would be identified [15, 16]. levels in culture supernatants were corrected for cell
number. Blood specimens were obtained from mice uponIn addition to exploring the effect of rapamycin on
the cell cycle progression of RCC 786-O and apoptosis, termination of in vivo experiments and the serum was
separated and stored at –20C until measurement of cyto-we examined its effect on the expression of VEGF-A
and TGF-1. Our focus on VEGF-A and TGF-1 was kine levels by ELISA. Species-specific VEGF-A ELISA
kits were used to measure mouse and human VEGF-Ainformed in part by the observations that the VHL gene
is mutated in human RCC 786-O and that the mutation protein levels in the mouse serum and human VEGF-A in
cell culture supernatants. TGF-1 kits, purchased fromis associated with over expression of tumor promoting
cytokines VEGF-A and TGF-1. R&D Systems (Minneapolis, MN, USA) were used to
measure circulating levels of mouse TGF-1 protein.
METHODS Immunohistochemistry
Cell lines, cell culture, and reagents Lungs from mice that received intravenous injection
of human RCC were retrieved and fixed in buffered-A well-characterized human RCC 786-O cell line was
obtained from ATCC (Rockville, MD, USA) [5]. An formalin solution, sectioned into 6 m thicknesses. Im-
munohistochemistry staining for endothelial cell markeradditional human RCC cell line, Porson, was a kind
gift of Dr. D. Nanus (Weill Medical College of Cornell factor VIII (von Willebrand factor) was performed using
antifactor VIII monoclonal antibody (DAKO, Carpin-University, New York, NY, USA). Human RCCs were
cultured in minimal essential medium (MEM), supple- teria, CA, USA). Antibody binding was localized with
the use of immunoperoxidase technique following themented with 10% fetal bovine serum (FBS) and penicillin/
streptomycin/l-glutamine (100 IU/50g/mL/2 mmol/L) manufacturer’s instructions.
(Life Technologies, Inc., Grand Island, NY, USA) and
Proliferation, cell cycle analysis, and apoptosis detectionat 37C and maintained in a 5% CO2/95% air atmosphere.
For the in vitro studies, the cells were harvested when Human RCC (2000 cells/well) were plated in 96-well
flat bottom tissue culture plate (Becton Dickinson Lab-they reached 70% to 80% confluence, washed with phos-
phate-buffered saline (PBS) and resuspended in MEM/ ware, Franklin Lakes, NJ, USA) and incubated at 37C in
a 5% CO2/95% air atmosphere. OneCi of 3H-thymidine10% FBS. Rapamycin was a gift from Dr. S. Seghal (Wy-
eth Laboratories, Philadelphia, PA, USA). Cyclosporine was added 6 hours prior to cell harvest. Proliferation
was quantified by measuring 3H-thymidine incorporationA (CsA) was purchased from Sigma (Sigma Chemical
Co., St. Louis, MO, USA). into DNA with the use of TopCountR liquid scintillation
counter (Packard, Meriden, CT, USA).
Measurement of mRNA by real-time quantitative Cell cycle analysis was performed with human RCC
polymerase chain reaction assay fixed in 70% ethanol and stained with a solution con-
taining hypotonic propidium iodide (Sigma Co.) andTotal RNA was isolated from the human RCC using
the RNeasy Mini kit (Qiagen, Valencia, CA, USA). To- RNAse. Flow cytometry study was carried out on an
Epic flow cytometer (Beckman-Coulter, Miami, FL,tal RNA (1 g) was reverse transcribed to cDNA using
TaqManR reverse transcription kit (Applied Biosystems, USA). The DNA histogram was analyzed using the Mod-
fit computer program (Verity Software House, Topsham,Branchburg, NJ, USA). Real-time quantitative polymer-
ase chain reaction (PCR) assay was performed with the ME, USA).
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The percentage of apoptotic cells was measured by
staining human RCC with phycoerythrin (PE)–labeled
annexin V (Pharmingen, Madison, WI, USA) and analy-
sis of treated RCC by flow cytometry to distinguish intact
viable RCC (annexin V–negative cells) from apoptotic
RCC (annexin V–positive cells).
Human RCC pulmonary metastasis model
Six- to 8-week-old SCID beige mice (Taconic) were
used to establish in vivo pulmonary metastasis model.
In brief, 2 105 786-O RCC in 0.5 mL PBS were injected
in the tail vein of SCID beige mice and treatment with
rapamycin, CsA or rapamycin and CsA was done accord-
ing to the following regimens. CsA (Novartis Pharmaceu-
tics, Summit, NJ, USA) was administered by the subcuta-
neous route at 20 mg/kg and the treatment was started
1 day prior to tumor inoculation and repeated every
other day until termination of the experiment. This dos-
age, as well as route of administration of CsA, consis-
tently increased metastatic progression of tumors of mu-
rine or human origin in BALB/C mice or SCID beige
mice [17]. Rapamycin (RapamuneR, Wyeth Laboratories,
Philadelphia, PA, USA) was administered by oral gavage
(2 mg/kg/day) started on day 3 after tumor inoculation
and continued on a daily basis. We have reported that
rapamycin, at this dosage, is effective in constraining
murine renal cancer progression in BALB/C mice [11].
The SCID beige mice treated with both CsA and rapa-
mycin received these drugs using the same schedule. The
mice were killed on day 30 (4) for the enumeration of
pulmonary metastasis. The number of pulmonary metas-
tasis was determined following endotracheal insuffl-
ations of lungs with 15% black India ink and bleaching
the collected lungs in Fekete’s solution [17]. The effect
of drug treatment on survival of tumor-inoculated mice
was determined by continuing drug treatment until the
death of animals.
Statistics
One-way analysis of variance and Bonferroni correc-
tion were performed to identify differences among multi-
ple groups. An independent or a paired t test was per-
formed to identify differences between two groups.
RESULTS
Rapamycin reduces human RCC pulmonary metastasis
Rapamycin treatment prevented the development
RCC pulmonary metastasis in SCID beige mice and a
representative example of its striking antitumor effect is
shown in Figure 1A. It is evident that rapamycin not
only reduced the number of metastasis but also reduced
the size of tumor nodules. It is also evident that CsA
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increased the number and size of metastatic nodules and
Fig. 1. Rapamycin reduces pulmonary metas-
tasis in severe combined immunodeficient
(SCID) beige mice. Human renal cancer cells
(RCC) 786-O (2  105 cells in 0.5 mL phos-
phate-buffered saline) were injected in the tail
vein of SCID beige mice. The mice were un-
treated (controls), treated with cyclosporine
(CsA), 20mg/kg/every other day, treated with
rapamycin (Rapa), 2mg/kg/day, or treated
with CsA, 20mg/kg/every other day, and Rapa,
2mg/kg/day (CsA/Rapa). (A) Representative
lungs retrieved 27 days after tumor inocula-
tion illustrate the reduction in RCC pulmo-
nary metastasis in rapamycin- or rapamycin
and cyclosporine-treated mice and the in-
crease in metastasis in cyclosporine-treated
mice as compared to control.
Fig. 5. Immunhistochemical analysis of lungs from tumor-bearing severe combined immunodeficient (SCID) beige mice. Human renal cancer
cells (RCC) 786-O (2  105 cells in 0.5 mL phosphate-buffered saline) were injected in the tail vein of SCID beige mice. The mice were untreated
(controls), treated with cyclosporine (CsA), 20 mg/kg/every other day, treated with rapamycin (Rapa), 2 mg/kg/day, or treated with cyclosporine,
20 mg/kg/every other day, and rapamycin, 2 mg/kg/day (CsA/Rapa). The lungs were retrieved 30 days after tumor inoculation and stained for von
Willebrand factor. Immunostaining was evident in the lungs from control mice or mice treated with cyclosporine alone and there was virtual lack
of staining for von Willebrand factor in the mice treated with rapamycin or cyclosporine and rapamycin (magnification 200).
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Fig. 2. Rapamycin prolongs the survival of tumor-inoculated severe
combined immunodeficient (SCID) beige mice. Human renal cancer
cells (RCC) 786-O (2  105 cells in 0.5 mL phosphate-buffered saline)
were injected in the tail vein of SCID beige mice. The mice were
untreated (controls), treated with cyclosporine, 20 mg/kg/every other
day, treated with rapamycin, 2 mg/kg/day, or treated with cyclosporine,
20 mg/kg/every other day, and rapamycin, 2mg/kg/day. Deaths were
recorded on a daily basis. The mean duration of survival was 54  3
Fig. 1. (continued) (B) The number of pulmonary metastases (mean  days in the control mice (N  13 mice), 42  2 days in cyclosporine-
SE) in untreated control mice was 344  32 (N  8 mice), 478  35 treated mice (N  16 mice), 108  8 days in rapamycin-treated mice
in cyclosporine-treated mice (N  10 mice), 156  28 in rapamycin- (N  8 mice), and 109  5 days in rapamycin and cyclosporine-treated
treated mice (N 11 mice) and 92  20 in rapamycin and cyclosporine- mice (N  9 mice) (P 	 0.0001, ANOVA). Multiple comparisons of
treated mice (N  13 mice) (P 	 0.0001, ANOVA). Multiple compari- all possible pairs of experimental groups showed that the mean survival
sons of all possible pairs of experimental groups showed that the mean time of rapamycin-treated group is significantly longer than that of
number of pulmonary metastasis in rapamycin-treated group is signifi- control mice (P 	 0.0001) and cyclosporine-treated mice (P 	 0.0001).
cantly lower than that of control mice (P 	 0.0001) and cyclosporine- The mean survival time of mice treated with both rapamycin and cyclo-
treated mice (P	 0.0001). The mean number of pulmonary metastasis in sporine was higher compared to control mice (P	 0.0001), cyclosporine-
mice treated with both rapamycin and cyclosporine was also significantly treated mice (P 	 0.0001), but not rapamycin-treated mice (P  0.83).
lower compared to control mice (P 	 0.0001), cyclosporine-treated
mice (P 	 0.0001), but not rapamycin-treated mice (P  0.098). The
mice were killed 30
/3 days after tumor inoculation and the number
of metastasis was counted as described in the Methods section.
survival time was 54  3 days in control mice (N  13
mice), 42  2 days in the mice treated with CsA (N 
that rapamycin was able to reduce pulmonary metastasis
16 mice), 108  8 days in mice treated with rapamycinin mice treated with CsA as well.
(N 8 mice), and 109 5 days in mice treated with CsAFigure 1B illustrates the number of pulmonary metas-
and rapamycin (N  9 mice). Comparison of treatmenttasis in SCID beige mice treated with CsA, rapamycin,
effects in the four experimental groups showed that theand CsA and rapamycin. The mean ( SE) number of
null hypothesis of equal group means should be rejectedRCC pulmonary metastases was 344  32 in the control
(P	 0.0001, ANOVA). Multiple comparisons of all pos-SCID beige mice (N  8 mice) and CsA treatment in-
sible pairs of experimental groups showed that the meancreased the number of metastases to 478  35 (N  10
survival time of rapamycin treated group is significantlymice). The number of metastases in mice treated with
longer than that of control mice (P 	 0.0001) and CsA-rapamycin was 155  28 (N  11 mice) and in mice
treated mice (P 	 0.0001). The mean survival time oftreated with both CsA and rapamycin the number was
92  20 (N  13 mice). Comparison of treatment effects mice treated with both CsA and rapamycin was higher
in the four experimental groups showed that the null compared to control mice (P	 0.0001), CsA-treated mice
hypothesis of equal group means should be rejected (P	 (P	 0.0001), but not rapamycin-treated mice (P  0.83).
0.0001, ANOVA). Multiple comparisons of all possible
pairs of experimental groups showed that the mean num- Mechanisms for the antitumor efficacy of rapamycin
ber of pulmonary metastasis in rapamycin treated group Rapamycin is a potent inhibitor of proliferation of
is significantly lower than that of control mice (P	 0.0001)
hemopoietic and lymphoid cells but has an inconsistentand CsA-treated mice (P 	 0.0001). The mean number
effect on the growth of cells of epithelial or mesenchymalof pulmonary metastasis in mice treated with both rapa-
origin. We examined whether rapamycin inhibited themycin and CsA was also significantly lower compared
growth of RCC 786-O derived from human tubular epi-to control mice (P 	 0.0001), CsA-treated mice (P 	
thelial cells. Rapamycin inhibited RCC 786-O cell growth0.0001), but not rapamycin-treated mice (P  0.098).
at a concentration that is readily accomplished in clinical
Impact of rapamycin on survival practice (Fig. 3A). Single-cell analysis by flow cytometry
showed that treatment with rapamycin alone or rapa-Treatment with rapamycin prolonged the survival of
tumor-bearing SCID beige mice (Fig. 2). The mean (SE) mycin plus CsA but not CsA alone blocked G1 to S
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Fig. 3. Inhibitory effect of rapamycin on hu-
man renal cancer (RCC) 786-O cells. (A) Hu-
man RCC 786-O cells were incubated alone
(control) (), in the presence of rapamycin
(Rapa, 10 ng/mL) (), cyclosporine (CsA
1000 ng/mL) (), or a combination of cyclo-
sporine (1000 ng/mL) and rapamycin (10 ng/
mL) (CsA/Rapa) (). Proliferation of RCC
786-O cells was quantified by determining 3H-
thymidine incorporation into DNA at indi-
cated time points. (B) RCC 786-O cells were
treated as described in (A) for 24 hours and
then stained with propidium iodide. ModFit
software analysis of flow cytometry histo-
grams revealed that rapamycin treatment or
treatment with cyclosporine and rapamycin
increased the percentage of cells in G0/G1
phase.
transition (Fig. 3B). Rapamycin did not affect cell viabil- rapamycin plus CsA for 24 hours or 48 hours, and levels
of VEGF-A mRNA were measured with the use of real-ity as assessed by trypan blue dye exclusion and did not
induce apoptosis of RCC (data not shown). time quantitative PCR assay. Results from three experi-
ments are summarized in Figure 4A. Treatment withThe VHL gene is mutated in human RCC 786-O and
the lack of wild-type VHL gene is associated with height- rapamycin resulted in reduced levels of VEGF-A mRNA
at every time point tested (P  0.0004 at 24 hours com-ened expression of VEGF-A [5, 10]. VEGF-A is consid-
ered to be a tumor angiogenesis factor and a reduction pared to control cells and P 0.001 at 48 hours compared
to control cells) and treatment with rapamycin plus CsAin VEGF-A expression is a potential mechanism for the
antitumor efficacy of rapamycin. We investigated the also resulted in a significant reduction in the level of
expression of VEGF-A mRNA at each of the time pointseffect of rapamycin on VEGF-A expression by RCC and
in mice treated with rapamycin. (P  0.0006 at 24 hours compared to control cells and
P  0.002 at 48 hours compared to control cells). CsARCC 788-O were treated with rapamycin, CsA, or
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Fig. 4. Effect of rapamycin on vascular endothelial growth factor (VEGF-A) expression by human renal cancer (RCC) 786-O cells. (A) RCC
788-O cells were treated with cyclosporine (CsA, 1000 ng/mL), rapamycin (Rapa, 10 ng/mL), or cyclosporine (1000 ng/mL) and rapamycin (10
ng/mL) (CsA/Rapa) for 24 hours or 48 hours and levels of VEGF-A mRNA were measured with the use of real-time quantitative polymerase
chain reaction (PCR) assay. Results (mean  SE) from three experiments are shown after normalization for constitutively expressed 18S rRNA.
Treatment with rapamycin resulted in reduced levels of VEGF-A mRNA at every time point tested (P  0.0004 at 24 hours compared to control
cells and P  0.001 at 48 hours compared to control cells) and treatment with rapamycin plus cyclosporine also resulted in a significant reduction
in the level of expression of VEGF-A mRNA at each of the time points (P  0.0006 at 24 hours compared to control cells and P  0.002 at 48
hours compared to control cells). Cyclosporine did not have significant effect on the level of expression of VEGF-A mRNA (P  0.05 at all time
points) as compared to control cells. (B) Cell free supernatants were collected from the RCC 788-O cells treated as described in (A) and the levels
of VEGF-A protein in the supernatants were measured with the use of enzyme-linked immunosorbent assay (ELISA). Results (mean  SE) from
three experiments are shown. Treatment of RCC 788-O cells with rapamycin alone (Rapa) (P  0.0006 at 24 hours compared to control cells and
P  0.003 at 48 hours compared to control cells) or treatment with rapamycin plus cyclosporine (CsA/Rapa) (P 	 0.0001 at 24 hours compared
to control cells and P  0.012 at 48 hours compared to control cells) resulted in a reduction in the level of expression of VEGF-A protein.
Treatment of RCC with cyclosporine (CsA) did not alter VEGF-A protein levels as compared to control cells (P  0.05 at both time points).
treatment neither decreased nor increased the level of line. In additional experiments, we found a similar inhibi-
tory effect when a different human RCC (RCC Porson)expression of VEGF-A mRNA compared to untreated
RCC (P  0.05 at all time points). was treated with rapamycin (data not shown).
Our in vitro studies demonstrated that rapamycin re-The inhibitory effect of rapamycin on VEGF-A ex-
pression was also evident at the protein level. Cell-free duces the level of expression of angiogenic VEGF-A
in human RCC. One potential in vivo consequence ofsupernatants were collected from the RCC 788-O treated
with rapamycin, CsA, or rapamycin plus CsA for 24 reduced expression of VEGF-A is a reduction in tumor
angiogenesis. We examined the lungs of tumor bearinghours or 48 hours and the levels of VEGF-A protein in
the supernatants were measured with the use of ELISA. SCID beige mice for microvessels. Immunohistochemi-
cal analysis of lung tissues demonstrated prominentResults from three experiments are summarized in Fig-
ure 4B. In accord with mRNA data, treatment of RCC staining for von Willebrand factor in control mice or
mice treated with CsA alone and virtual lack of staining788-O with rapamycin alone (P  0.0006 at 24 hours
compared to control cells and P  0.003 at 48 hours for von Willebrand factor in the mice treated with rapa-
mycin or rapamycin and CsA (Fig. 5).compared to control cells) or treatment with rapamycin
plus CsA resulted in a significant reduction in the level We investigated whether treatment with rapamycin
reduced circulating levels of VEGF-A protein. Becauseof expression of VEGF-A protein (P 	 0.0001 at 24
hours compared to control cells and P  0.012 at 48 VEGF-A levels might be due to both RCC-derived
VEGF-A (human VEGF-A) and endogenous VEGF-Ahours compared to control cells). Treatment of RCC
with CsA alone neither stimulated nor inhibited VEGF-A (mouse VEGF-A), we used species specific ELISA and
measured the levels of VEGF-A in untreated mice, miceexpression at the protein level compared to untreated
cells (P  0.05 at both time points). treated with rapamycin, mice treated with CsA, and mice
treated with both rapamycin and CsA. Human VEGF-AThe reduction in VEGF-A expression, observed at the
mRNA level and protein level, following treatment of was not detected in the blood of any of the mice studied,
whereas mouse VEGF-A was detected in all of the miceRCC 788-O with rapamycin was not unique to this cell
Luan et al: Immunosuppressive drugs and tumor progression924
Fig. 6. Circulating levels of vascular endothelial growth factor (VEGF-A) or transforming growth factor-1 (TGF-1) in tumor-bearing severe
combined immunodeficient (SCID) beige mice. Human renal cancer cells (RCC) 786-O (2  105 cells in 0.5 mL phosphate-buffered saline) were
injected in the tail vein of SCID beige mice. The mice were untreated (controls), treated with cyclosporine (CsA), 20 mg/kg/every other day,
treated with rapamycin (Rapa), 2 mg/kg/day, or treated with cyclosporine, 20 mg/kg/every other day and rapamycin, 2mg/kg/day (CsA/Rapa).
Blood was obtained 30 days after tumor inoculation and circulating levels of VEGF-A or TGF-1 protein was measured with the use of enzyme-
linked immunosorbent assay (ELISA). (A) The circulating levels of VEGF-A (mean  SE) in untreated control mice was 69  4 pg/mL (N  5
mice), 73  8 pg/mL in cyclosporine-treated mice (CsA) (N  5 mice), 56  8 pg/mL in rapamycin-treated mice (Rapa) (N  4 mice) and 66 
3 pg/mL in rapamycin and cyclosporine-treated mice (CsA/Rapa) (N  5mice) (P  0.65, ANOVA). (B) The mean ( SE) level of TGF-1
protein was 66  5 g/mL in control mice (N  5 mice), 72  3 g/mL in the mice treated with cyclosporine (CsA) (N  5 mice), 40  4 g/mL
in mice treated with rapamycin (Rapa) (N  4 mice), and 53  5 g/mL in mice treated with rapamycin plus cyclosporine (CsA/Rapa) (N  5
mice) (P  0.0009, ANOVA). Multiple comparisons of all possible pairs of experimental groups showed that the circulating levels of TGF-1 in
rapamycin-treated group is significantly lower than that of control mice (P  0.001) and cyclosporine-treated mice (P  0.0002). The mean levels
of TGF-1 in mice treated with both rapamycin and cyclosporine was lower compared with cyclosporine-treated mice (P  0.007), but not
significantly different from rapamycin-treated mice (P  0.06).
studied. Figure 6A shows the circulating levels of mouse (N  5 mice), 72  3 g/mL in the mice treated with
VEGF-A in the four experimental groups. The mean CsA (N  5 mice), 40  4 g/mL in mice treated with
(SE) circulating level of mouse VEGF-A in untreated rapamycin (N  4 mice), and 53  5 g/mL in mice
control mice was 69  4 pg/mL (N  5mice), 73  8 treated with rapamycin plus CsA (N 5 mice). Compari-
pg/mL in CsA-treated mice (N  5 mice), 56  8 pg/mL son of treatment effects in the four experimental groups
in rapamycin-treated mice (N  4 mice), and 66  3 showed that the null hypothesis of equal group means
pg/mL in rapamycin and CsA-treated mice (N  5). should be rejected (P 0.0009, ANOVA). Multiple com-
Although the VEGF-A levels were numerically lower parisons of all possible pairs of experimental groups
in the rapamycin or rapamycin plus CsA-treated mice, showed that the circulating levels of TGF-1 in rapa-
as compared to control or CsA-treated mice, comparison mycin-treated group is significantly lower than that of
of treatment effects in the four experimental groups control mice (P  0.0012) and CsA-treated mice (P 
showed that the null hypothesis of equal group means 0.0002). The mean levels of TGF-1 in mice treated with
should not be rejected (P  0.65, ANOVA). both rapamycin and CsA was also lower compared CsA-
TGF-1 is an inducer of VEGF-A expression and anti- treated mice (P  0.0072), but not significantly different
bodies directed at TGF- reduce tumor angiogenesis, from rapamycin-treated mice (P  0.06).
block tumor growth and metastatic progression [6, 17].
A potential mechanism for the reduced circulating levels
DISCUSSIONof VEGF-A and antitumor efficacy of rapamycin is a
The new observation that has emerged from our novelreduction in circulating levels of TGF-1. We examined
model of human RCC pulmonary metastasis is that thethis hypothesis by measuring levels of TGF-1 in control
macrolide rapamycin is highly effective in constrainingmice, mice treated with rapamycin, mice treated with
metastatic tumor progression. Our mechanistic studiesCsA, and in mice treated with both rapamycin and CsA.
support the idea that the antitumor efficacy of rapamycinTreatment of tumor-inoculated SCID beige mice with
is realized, at least in part, by targeted reduction of tumorrapamycin resulted in a significant reduction in the circu-
promoting cytokines VEGF-A and TGF-1.lating level of TGF-1 (Fig. 6B). The mean (SE) level
of TGF-1 protein was 66  5 g/mL in control mice Currently, RCC poses a significant treatment challenge
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once distance metastasis has been established because to compensate for the loss of p70S6 kinase activity
prompted us to examine whether rapamycin preventedof the resistance to both chemotherapy and radiotherapy
[18]. Spontaneous regression of metastatic tumor occurs the progression of human RCC 786-O from G1 phase
cells to S phase. Our single-cell analysis with the use ofinfrequently and the overall survival rate in patients with
RCC is dismal [19]. Surgical approaches have a well- flow cytometry demonstrated that the RCC is indeed
sensitive to rapamycin and that this cell line of epithelialestablished role in localized disease and there is some
support for the therapeutic strategy of combining surgi- origin is growth arrested at the G1 checkpoint. Our stud-
ies also showed that CsA does not block cell cycle pro-cal resection with other modalities such as chemotherapy
or biotherapy in the unfortunate patient with metastatic gression and that rapamycin mediated cell cycle arrest
at the G1 checkpoint in human RCC conditioned withdisease [3, 20, 21]. Cytokine-based immunotherapy with
interferon- and IL-2, in addition to troublesome side both rapamycin and CsA. We hypothesize that the po-
tent antiproliferative activity of rapamycin is a contribu-effects, yields unpredictable results as well. In renal
transplant recipients, the incidence is 10 to 100 times tor to its antitumor efficacy.
Rapamycin has been shown to induce apoptotic cellhigher than that in the general population [12–14] and
the clinical course is particularly aggressive and leads to death of some human tumor cell lines, presumably by
blocking insulin-like growth factor-1 (IGF-1) mediateddeath in a short period of time [15, 16].
Rapamycin was approved by the United States Fed- cell growth [22]. Our evaluation, with the use of annexin
V binding to externalized phosphatidylserine as a markereral Food and Drug Administration for clinical use in
recipients of renal allografts. Although immunosuppres- of apoptotic cells, failed to implicate apoptosis of human
RCC as a mechanism for the rapamycin associated re-sive drugs generally enhance tumor progression in exper-
imental models, rapamycin is effective in blocking the duction in the tumor burden.
Loss of function mutations in VHL gene is associatedgrowth of a number of tumor cell lines. Indeed, we re-
cently demonstrated that rapamycin is highly effective with over expression of angiogenic factors such as
VEGF-A [10]. Indeed, RCC is distinguished for its hyp-in preventing the growth and metastatic progression of
murine RCC [11]. ervascularity and it is likely that its ability to produce
multiple angiogenic factors is an important mechanismThe results of the current investigation are of potential
clinical significance for a number of reasons. First, we for its exuberant growth [8, 23, 24]. Our data showing
that rapamycin inhibited the ability of human RCC toused a human RCC cell line as the tumor challenge.
Second, we developed a human RCC pulmonary metas- produce VEGF-A at the transcriptional level is a candi-
date mechanism for the antitumor effect of rapamycin.tasis model that bears several similarities to the clinical
situation and explored rapamycin’s antitumor activity. The ability to block tumor cell production of VEGF-A
might be a potential explanation for our immunohisto-Third, therapy was initiated after the establishment of
metastasis. Fourth, “clinical effectiveness” was accom- chemical studies showing a virtual lack of staining for
endothelial cells in rapamycin-treated mice. Our studies,plished with oral administration of rapamycin and with
the dosage that promotes allograft survival and one that however, fail to distinguish whether the marked reduc-
tion of neovascularization in rapamycin-treated mice isis unattended by toxicity. Fifth, the efficacy was demon-
strated not only by a reduction in the number and size the cause of tumor growth inhibition or simply the conse-
quence of a less tumor burden in rapamycin-treatedof metastatic nodules but also by a striking increase in
survival time. The doubling of survival time observed mice. It is also possible that the direct growth inhibitory
effect of rapamycin on endothelial cells might be respon-with rapamycin treatment is significant in the light of
observation that approved therapy such as IL-2 prolongs sible for the reduced neovascularization [25].
Ananth et al [6] have reported that human RCC 786-Othe survival of mice with murine RCC only by 10 to15
days. Sixth, we demonstrate that rapamycin is effective over-express TGF-1 and that introduction of wild-type
VHL gene reduces TGF-1 mRNA and protein levelswhen used in conjunction with CsA, which by itself pro-
motes tumor progression [17]. That rapamycin is effica- [6]. These investigators also reported that antibodies di-
rected at TGF- reduce tumor microvessel count andcious in the context of CsA is of considerable clinical
significance since the drug combination of CsA plus rapa- subcutaneous tumor growth. We have reported that anti-
TGF- monoclonal antibodies reduce murine RCC pul-mycin is an approved therapy for the prevention of renal
allograft rejection. Finally, our study incorporated mech- monary metastasis in SCID beige mice [17]. An excess
of TGF-1 has also been implicated in the metastaicanistic evaluation that has yielded insights into the biol-
ogy of tumor regulation. progression of human breast cancer [26]. Thus, our ob-
servation that the circulating levels of TGF-1 are lowerRapamycin is an effective inhibitor of proliferation
of hemopoietic and lymphoid cells. Its antiproliferative in rapamycin-treated mice offers a mechanism for the
drug’s ability to reduce pulmonary metastasis and pro-effect on epithelial cells, however, is inconsistent. The
lack of a consistent effect and the ability of some cells long survival.
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of messenger RNAs for vascular endothelial growth factor andWe have reported that rapamycin prevents metastatic
placenta growth factor in renal cell carcinoma associated with
progression of murine RCC [11]. Guba et al [27] observed angiogenesis. Cancer Res 54:4233–4237, 1994
9. Nicol D, Hii SI, Walsh M, et al: Vascular endothelial growththat rapamycin constrains metastatic tumor growth of
factor expression is increased in renal cell carcinoma. J UrolCT-26 mouse colon adenocarcinoma cells in BALB/C
157:1482–1486, 1997
mice. Majewski et al [28] have demonstrated that RAD, 10. Siemeister G, Weindel K, Mohrs K, et al: Reversion of deregu-
lated expression of vascular endothelial growth factor in humanan analog of rapamycin, inhibits subcutaneous growth
renal carcinoma cells by von Hippel-Lindau tumor suppressor pro-of Epstein-Barr virus positive B cells in SCID mice. These
tein. Cancer Res 56:2299–2301, 1996
new observations confirm and extend the findings, reported 11. Luan FL, Hojo M, Maluccio M, et al: Rapamycin blocks tumor
progression: unlinking immunosuppression from antitumor effi-almost two decades ago [29, 30], that the macrolide rapa-
cacy. Transplantation 73:1565–1572, 2002mycin is effective against multiple tumor types [29, 30].
12. Kliem V, Kolditz M, Behrend M, et al: Risk of renal cell carci-
noma after kidney transplantation. Clin Transplant 11:255–258,
1997
CONCLUSION 13. Doublet JD, Peraldi MN, Gattegno B, et al: Renal cell carcinoma
of native kidneys: prospective study of 129 renal transplant patients.The human RCC pulmonary metastasis model, which
J Urol 158:42–44, 1997
bears several similarities to the clinical course of RCC, 14. Sheil AG, Disney AP, Mathew TH, Amiss N: De novo malignancy
emerges as a major cause of morbidity and late failure in renaldemonstrates that rapamycin reduces pulmonary metas-
transplantation. Transplant Proc 25:1383–1384, 1993tases and prolongs survival of the tumor-bearing host.
15. Pope JC, Koch MO, Bluth RF: Renal cell carcinoma in patients
Our observations support the idea that rapamycin might with end-stage renal disease: a comparison of clinical significance
in patients receiving hemodialysis and those with renal transplants.be of value in the management of patients with renal
Urology 44:497–501, 1994cancer. That rapamycin is effective in the absence of T
16. Penn I: Primary kidney tumors before and after renal transplanta-
cell, B cell, and NK cell immunity and even in the pres- tion. Transplantation 59:480–485, 1995
17. Hojo M, Morimoto T, Maluccio M, et al: Cyclosporine inducesence of CsA makes our hypothesis even more compelling
cancer progression by a cell-autonomous mechanism. Naturefor the transplant recipient in whom the standard ap-
397:530–534, 1999
proach is to reduce immunosuppressive therapy once 18. Yagoda A, Abi-Rached B, Petrylak D: Chemotherapy for ad-
vanced renal-cell carcinoma: 1983–1993. Semin Oncol 22:42–60,malignancy is detected.
1995
19. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic
ACKNOWLEDGMENTS stratification of 670 patients with advanced renal cell carcinoma.
J Clin Oncol 17:2530–2540, 1999This work was supported in part by an award from NIH/NIAID,
20. Tanguay S, Swanson DA, Putnam JB, Jr: Renal cell carcinomaRO1 AI26932. Dr. W.J. Chon is the recipient of a research fellowship
metastatic to the lung: potential benefit in the combination ofaward from the Kidney & Urology Foundation of America. We thank
biological therapy and surgery. J Urol 156:1586–1589, 1996Dr. D. Nanus for the generous gift of human renal cancer line Porson,
21. Walther MM, Yang JC, Pass HI, et al: Cytoreductive surgeryDr. P. August for critical review, and Ms. L. Stackhouse for meticulous
before high dose interleukin-2 based therapy in patients with meta-preparation of the manuscript. We dedicate our paper to the memory
static renal cell carcinoma. J Urol 158:1675–1678, 1997of Suren N. Sehgal, Ph.D., the discoverer of rapamycin, a brilliant
22. Dilling MB, Dias P, Shapiro DN, et al: Rapamycin selectivelyscientist and a man of high integrity.
inhibits the growth of childhood rhabdomyosarcoma cells through
inhibition of signaling via the type I insulin-like growth factorReprint request to Manikkam Suthanthiran, M.D., 525 East 68th Street,
receptor. Cancer Res 54:903–907, 1994Box 3, New York, NY, 10021 USA
23. Wechsel HW, Bichler KH, Feil G, et al: Renal cell carcinoma:E-mail: msuthan@med.cornell.edu
Relevance of angiogenetic factors. Anticancer Res 19:1537–1540,
1999
REFERENCES 24. Thelen P, Hemmerlein B, Kugler A, et al: Quantification by
competitive quantitative RT-PCR of VEGF-A121 and VEGF-1. Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics,
A165 in renal cell carcinoma. Anticancer Res 19:1563–1565, 19991994. CA Cancer J Clin 44:7–26, 1994
25. Yu Y, Sato JD: MAP kinases, phosphatidylinositol 3-kinase, and2. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N
p70 S6 kinase mediate the mitogenic response of human endothe-Engl J Med 335:865–875, 1996
lial cells to vascular endothelial growth factor. J Cell Physiol3. Flanigan RC, Salmon SE, Blumenstein BA, et al: Nephrectomy
178:235–246, 1999followed by interferon alfa-2b compared with interferon alfa-2b
26. Yin JJ, Selander K, Chirgwin JM, et al: TGF-beta signaling block-alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659,
ade inhibits PTHrP secretion by breast cancer cells and bone metas-2001
tases development. J Clin Invest 103:197–206, 19994. Linehan WM, Lerman MI, Zbar B: Identification of the von Hip-
27. Guba M, von Breitenbuch P, Steinbauer M, et al: Rapamycinpel-Lindau (VHL) gene. Its role in renal cancer. JAMA 273:564–
inhibits primary and metastatic tumor growth by antiangiogenesis:570, 1995
Involvement of vascular endothelial growth factor. Nat Med 8:128–5. Iliopoulos O, Kibel A, Gray S, Kaelin WG, Jr: Tumour suppres-
135, 2002sion by the human von Hippel-Lindau gene product. Nat Med
28. Majewski M, Korecka M, Kossev P, et al: The immunosuppressive1:822–826, 1995
macrolide RAD inhibits growth of human Epstein-Barr virus-6. Ananth S, Knebelmann B, Gruning W, et al: Transforming
transformed B lymphocytes in vitro and in vivo: A potential ap-growth factor beta1 is a target for the von Hippel-Lindau tumor
proach to prevention and treatment of posttransplant lymphoproli-suppressor and a critical growth factor for clear cell renal carci-
ferative disorders. Proc Natl Acad Sci USA 97:4285–4290, 2000noma. Cancer Res 59:2210–2216, 1999
29. Douros J, Suffness M: New antitumor substances of natural ori-7. Knebelmann B, Ananth S, Cohen HT, Sukhatme VP: Trans-
gin. Cancer Treat Rev 8:63–87, 1981forming growth factor alpha is a target for the von Hippel-Lindau
30. Cp E, Sehgal SN, Vezina C: Activity of rapamycin (AY-22,989)tumor suppressor. Cancer Res 58:226–231, 1998
8. Takahashi A, Sasaki H, Kim SJ, et al: Markedly increased amounts against transplanted tumors. J Antibiot (Tokyo) 37:1231–1237, 1984
